Merus Announces First Patient Dosed In The Phase 2 Trial Evaluating Petosemtamab Monotherapy In Heavily Pretreated Metastatic Colorectal Cancer
Merus Announces First Patient Dosed In The Phase 2 Trial Evaluating Petosemtamab Monotherapy In Heavily Pretreated Metastatic Colorectal Cancer
Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics) for cancer, today announced that the first patient has been dosed in the Company's phase 2 trial evaluating petosemtamab monotherapy in heavily pretreated (3L+) metastatic colorectal cancer (mCRC). Petosemtamab is a Biclonics targeting EGFR and LGR5.
Merus N.V.（納斯達克股票代碼：MRUS）是一家爲癌症開發創新的全長多特異性抗體（Biclonics和Triclonics）的臨床階段腫瘤公司，今天宣佈，該公司評估petosemtamab單一療法用於高度預處理（3L+）轉移性結直腸癌（mCRC）的2期試驗已爲首位患者服藥。Petosemtamab 是一種針對 EGFR 和 LGR5 的 Biclonics。
The phase 2, open-label trial will evaluate the safety and antitumor activity of petosemtamab monotherapy in 3L+ mCRC, post anti-EGFR therapy. To be eligible for enrollment, patients must lack certain mutations as detected in plasma by ctDNA NGS, including KRAS, NRAS.
這項2期開放標籤試驗將評估petosemamab單一療法在抗表皮生長因子治療後的3L+ mCRC中的安全性和抗腫瘤活性。要獲得入組資格，患者必須缺少ctDNA NGS（包括KRAS，NRAS）在血漿中檢測到的某些突變。
